FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016156617> ?p ?o ?g. }

• W2016156617 endingPage "788" @default.
• W2016156617 startingPage "779" @default.
• W2016156617 abstract "BACKGROUND The optimal treatment strategy for elderly patients with advanced nonsmall cell lung carcinoma has not been defined to date. The authors performed a retrospective analysis of a Phase III trial that treated patients who had Stage IIIB or IV nonsmall cell lung carcinoma with carboplatin and paclitaxel and analyzed the impact of age on response rate, survival, toxicity, and quality of life. METHODS Patients with Stage IIIB or IV NSCLC were randomized to receive either 4 cycles of carboplatin at an area under the curve (AUC) of 6 and paclitaxel at a dose of 200 mg/m2 every 21 days or treatment with carboplatin and paclitaxel (C/P) until they developed disease progression. At the time of disease progression, all patients on both arms were to receive second-line weekly paclitaxel at a dose of 80 mg/m2 per week. In this analysis, patients age 70 years and older were compared with patients younger than age 70 years. In addition, a minimum log rank P value analysis was performed in an attempt to identify other potential age splits that may have been significant. RESULTS Two hundred thirty patients were randomized. Sixty-seven patients were age 70 years or older (29%). The median number of cycles delivered for both age groups was 4 cycles (range, 0–19 cycles). No statistically significant differences in any of the most common toxicities (Grade ≥ 2) associated with C/P were identified (data from Cycles 1–4) for patients younger than age 70 years compared with patients age 70 years and older, respectively, including neutropenia (38% vs. 35%), neuropathy (13% vs. 16%), leukopenia (7% vs. 13%), myalgia/arthralgia (15% vs. 9%), malaise (8% vs. 15%), anemia (9% vs. 4%), thrombocytopenia (7% vs. 9%), anorexia (8% vs. 4%), and nausea/emesis (14% vs. 15%). In addition, no potential age splits that may have been significant were found using a minimum log rank P value analysis. CONCLUSIONS The current analysis demonstrated that C/P exhibited similar toxicity profiles in patients age 70 years and older compared with patients younger than age 70 years. The survival rates were not different between the two age groups, and there was no difference in progression of quality-of-life outcomes. In fit, elderly patients, C/P represented a reasonable standard regimen. Cancer 2003;98:779–88. © 2003 American Cancer Society." @default.
• W2016156617 created "2016-06-24" @default.
• W2016156617 creator A5036321069 @default.
• W2016156617 creator A5055925608 @default.
• W2016156617 creator A5059501045 @default.
• W2016156617 creator A5075076630 @default.
• W2016156617 creator A5078629724 @default.
• W2016156617 date "2003-08-01" @default.
• W2016156617 modified "2023-10-14" @default.
• W2016156617 title "The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel" @default.
• W2016156617 cites W1898736255 @default.
• W2016156617 cites W1935885922 @default.
• W2016156617 cites W1971345888 @default.
• W2016156617 cites W1974270126 @default.
• W2016156617 cites W1976182450 @default.
• W2016156617 cites W1979506839 @default.
• W2016156617 cites W1982492706 @default.
• W2016156617 cites W1991469663 @default.
• W2016156617 cites W1999094883 @default.
• W2016156617 cites W2037045305 @default.
• W2016156617 cites W2037139573 @default.
• W2016156617 cites W2070924227 @default.
• W2016156617 cites W2075940287 @default.
• W2016156617 cites W2083461199 @default.
• W2016156617 cites W2127305631 @default.
• W2016156617 cites W2140872365 @default.
• W2016156617 cites W2145188374 @default.
• W2016156617 cites W2165048128 @default.
• W2016156617 cites W2331849216 @default.
• W2016156617 cites W2607182122 @default.
• W2016156617 cites W4239714259 @default.
• W2016156617 cites W71298900 @default.
• W2016156617 doi "https://doi.org/10.1002/cncr.11548" @default.
• W2016156617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12910523" @default.
• W2016156617 hasPublicationYear "2003" @default.
• W2016156617 type Work @default.
• W2016156617 sameAs 2016156617 @default.
• W2016156617 citedByCount "127" @default.
• W2016156617 countsByYear W20161566172012 @default.
• W2016156617 countsByYear W20161566172013 @default.
• W2016156617 countsByYear W20161566172014 @default.
• W2016156617 countsByYear W20161566172015 @default.
• W2016156617 countsByYear W20161566172016 @default.
• W2016156617 countsByYear W20161566172017 @default.
• W2016156617 countsByYear W20161566172018 @default.
• W2016156617 countsByYear W20161566172019 @default.
• W2016156617 countsByYear W20161566172020 @default.
• W2016156617 countsByYear W20161566172021 @default.
• W2016156617 countsByYear W20161566172022 @default.
• W2016156617 countsByYear W20161566172023 @default.
• W2016156617 crossrefType "journal-article" @default.
• W2016156617 hasAuthorship W2016156617A5036321069 @default.
• W2016156617 hasAuthorship W2016156617A5055925608 @default.
• W2016156617 hasAuthorship W2016156617A5059501045 @default.
• W2016156617 hasAuthorship W2016156617A5075076630 @default.
• W2016156617 hasAuthorship W2016156617A5078629724 @default.
• W2016156617 hasConcept C126322002 @default.
• W2016156617 hasConcept C126894567 @default.
• W2016156617 hasConcept C141071460 @default.
• W2016156617 hasConcept C143998085 @default.
• W2016156617 hasConcept C146357865 @default.
• W2016156617 hasConcept C151730666 @default.
• W2016156617 hasConcept C2776256026 @default.
• W2016156617 hasConcept C2776283816 @default.
• W2016156617 hasConcept C2776694085 @default.
• W2016156617 hasConcept C2777292972 @default.
• W2016156617 hasConcept C2777546739 @default.
• W2016156617 hasConcept C2778239845 @default.
• W2016156617 hasConcept C2781451048 @default.
• W2016156617 hasConcept C29730261 @default.
• W2016156617 hasConcept C71924100 @default.
• W2016156617 hasConcept C86803240 @default.
• W2016156617 hasConcept C90924648 @default.
• W2016156617 hasConceptScore W2016156617C126322002 @default.
• W2016156617 hasConceptScore W2016156617C126894567 @default.
• W2016156617 hasConceptScore W2016156617C141071460 @default.
• W2016156617 hasConceptScore W2016156617C143998085 @default.
• W2016156617 hasConceptScore W2016156617C146357865 @default.
• W2016156617 hasConceptScore W2016156617C151730666 @default.
• W2016156617 hasConceptScore W2016156617C2776256026 @default.
• W2016156617 hasConceptScore W2016156617C2776283816 @default.
• W2016156617 hasConceptScore W2016156617C2776694085 @default.
• W2016156617 hasConceptScore W2016156617C2777292972 @default.
• W2016156617 hasConceptScore W2016156617C2777546739 @default.
• W2016156617 hasConceptScore W2016156617C2778239845 @default.
• W2016156617 hasConceptScore W2016156617C2781451048 @default.
• W2016156617 hasConceptScore W2016156617C29730261 @default.
• W2016156617 hasConceptScore W2016156617C71924100 @default.
• W2016156617 hasConceptScore W2016156617C86803240 @default.
• W2016156617 hasConceptScore W2016156617C90924648 @default.
• W2016156617 hasIssue "4" @default.
• W2016156617 hasLocation W20161566171 @default.
• W2016156617 hasLocation W20161566172 @default.
• W2016156617 hasOpenAccess W2016156617 @default.
• W2016156617 hasPrimaryLocation W20161566171 @default.
• W2016156617 hasRelatedWork W1502181122 @default.
• W2016156617 hasRelatedWork W1567229547 @default.
• W2016156617 hasRelatedWork W1989958874 @default.

• next